N/A
N=403
Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
Pneumonia · Pelvic Inflammatory Disease
Bottom Line
View on ClinicalTrials.gov: NCT01671280 ↗Enrolled (actual)
403
Serious AEs
10.8%
Results posted
Apr 2017
Primary outcome: Primary: Number of Participants With Treatment-Related Adverse Events — 39; 7 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Azithromycin IV (Drug)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Apr 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Treatment-Related Adverse Events |
39; 7 | — |
| SECONDARY Clinical Effectiveness Rate in Participants With Pneumonia |
89.6 | — |
| SECONDARY Clinical Effectiveness Rate in Participants With Pelvic Inflammatory Disease |
91.2 | — |
Summary
To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice
Eligibility Criteria
Inclusion Criteria
- Male or Female patients who are prescribed Zithromac IV for pneumonia or pelvic inflammatory disease.
Exclusion Criteria
- Subjects who have been prescribed Zithromac IV for pneumonia or pelvic inflammatory disease.
Data sourced from ClinicalTrials.gov (NCT01671280). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.